John Rim

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more: https://bit.ly/cellngene #CellandGeneTherapy #CellTherapy #GeneTherapy

15

🚀 A big shout to Llinks Team Advice on Strategic Biopharma Collaboration, Strengthening Shanghai Allist Pharmaceuticals Co., Ltd’s Oncology Pipeline 🚀 Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH) has signed a strategic collaboration with Jacobio Pharma (1167.HK), securing exclusive rights in Greater China for the KRAS G12C inhibitor Goralresib and SHP2 inhibitor JAB-3312. This partnership strengthens Allist's cancer treatment pipeline, with Goralresib already under priority review and JAB-3312 in Phase III trials. 💼 This partnership not only strengthens Allist’s oncology pipeline, targeting lung, pancreatic, and colorectal cancers, but also positions us to bring innovative treatments to patients in need. Notably, Goralresib's New Drug Application for second-line NSCLC with KRAS G12C mutation has received priority review as of May 21, 2024. Meanwhile, JAB-3312, as the first SHP2 inhibitor to enter a pivotal clinical trial, is set to offer a new treatment option with its unique “dual oral therapy” approach. 🎯 In this significant transaction, Llinks legal team(Head partner Xun Yang) provided comprehensive legal services to Allist Pharmaceuticals. From strategizing and drafting the licensing agreement to negotiations and advising on critical issues such as international multicenter cooperation and clinical development handover, Llinks' expertise has once again been integral in driving forward Allist's business development (BD) initiatives. 🔑 #AllistPharma #JACOBIOPharma #OncologyInnovation #LegalServices #TechLaw #Biopharma #StrategicPartnership #ClinicalTrials #KRASG12C #SHP2Inhibitor #Oncology #Biopharma #LegalServices #StrategicPartnership #ClinicalTrials #Innovation

4

댓글 1

𝐀𝐮𝐭𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 & 𝐍𝐨𝐧-𝐬𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐓𝐫𝐞𝐧𝐝𝐬 [𝟐𝟎𝟐𝟗] 𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑷𝑫𝑭 𝑩𝒓𝒐𝒄𝒉𝒖𝒓𝒆>> bit.ly/3RUOerG 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬 Drivers ·        Rising approvals for CAR T-cell therapies ·        Increasing R&D investments in autologous therapeutics ·        Increasing demand for personalized medicine  Restraints ·        Uptake of allogeneic cell-based therapies as substitutes  Opportunities ·        Rising outsourcing of manufacturing activities ·        Adoption of closed automated systems  Challenges ·        Stringent regulatory guidelines and reimbursement challenges ·        Issues associated with scalable manufacturing The #NorthAmerican region is expected to register the highest #CAGR of the autologous stem cell & non-stem cell therapies market. The rising investments for autologous stem cell and non-stem cell-based research, expansion of the healthcare sector, growing #cancer prevalence, and the increasing approval and adoption of autologous stem cell and non-stem cell-based therapies for treating cancer and other #chronicdiseases are expected to aid market growth in North America. Gilead Sciences, Bristol Myers Squibb, Johnson & Johnson, Vericel® Corporation, Novartis, Iovance Biotherapeutics, Inc., APAC Biotech, REGROW BIOSCIENCES, healiva®, Green Cross Health, Sanpower Group, ImmunoACT, CARsgen Therapeutics, IASO BioTherapeutics（驯鹿生物）, Pharmicell Co.,Ltd., Anterogen, ProKidney Corp., BioCardia, Inc., Neuroplast, ADAPTIMMUNE THERAPEUTICS PLC, AgonOx, Inc., Kyverna Therapeutics, Obsidian Therapeutics, Avotres Inc., CorestemChemon Inc., Juventas Cell Therapy Corp. #stemcelltherapies #autologousstemcells #regenerativemedicine #celltherapymarket #nonstemcelltherapies #medicalinnovation #biotech #healthtech #therapeuticadvancements #futureofmedicine #celltherapyresearch #personalizedmedicine

1

JD BIOSCIENCE views the FDA approval of Madrigal Pharmaceuticals’ #Rezdiffra (#resmetirom) as a promising entry point into the #NASH treatment market. While Rezdiffra reduces liver fat, it reportedly has limited impact on liver #fibrosis—a gap JD aims to address. https://lnkd.in/gvuvktXe

2

𝐖𝐞𝐚𝐫𝐚𝐛𝐥𝐞 𝐈𝐧𝐣𝐞𝐜𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬, 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/gbKawvWg The global healthcare landscape is rapidly evolving, and wearable injectors are at the forefront of this transformation. These innovative devices are reshaping how patients manage chronic diseases, enabling convenient, at-home administration of biologics and other large-volume medications. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: The market is experiencing significant growth due to the rising prevalence of chronic diseases, such as diabetes and cancer, which require frequent drug administration. Technological advancements and increased patient preference for self-administration are driving demand for wearable injectors. Companies are focusing on improving device design, patient comfort, and integrating smart technology to enhance user experience. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Pfizer Gerresheimer AbbVie West Pharmaceutical Services Ypsomed AG Amgen Medtronic Insulet Corporation 𝐅𝐮𝐭𝐮𝐫𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: With more patients seeking personalized healthcare solutions, the wearable injectors market is set to witness exponential growth. Market research indicates promising opportunities for biopharma companies and device manufacturers to innovate and cater to this growing demand. 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/gX6kgCyy Stay tuned for more in-depth insights into the future of healthcare and emerging technologies! #healthcareinnovation #wearableinjectors #marketresearch #biopharma #medicaldevices #chronicdisease #drugdelivery #patientcare #healthcaretech #wearabletechnology #marketresearch

1

The #Pruritus_Therapeutics market in China is poised for remarkable growth, driven by the nation's evolving #demographic landscape and rising #healthcare demands. #Valued at a staggering US$ 1,025.8 million in 2023, this market is projected to surpass US$ 1,711.1 million by 2032, reflecting a robust #CAGR of 5.58% during the forecast period of 2024–2032. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐎𝐮𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐅𝐫𝐞𝐞: https://lnkd.in/g23DKxmg The urban populace, comprising over 60% of the total, faces heightened exposure to environmental #pollutants, leading to a higher incidence of skin #conditions. Moreover, the prevalence of diseases like atopic #dermatitis has increased by approximately 5% in the past decade, further #fueling the demand for effective #therapeutic solutions. With around 30% of the population suffering from skin conditions #involving pruritus, the market's potential is undeniable. 𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐂𝐡𝐢𝐧𝐚 𝐏𝐫𝐮𝐫𝐢𝐭𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 3SBio Inc. Abbott Laboratories - Lafrancol S.A.S AbbVie Amgen Beijing Tide Pharmaceutical Co., Ltd. Eisai Co., Ltd. MYALNA group Pfizer Sanofi Sumitomo Dainippon Pharma #PruritusTherapeutics #SkinCareMarket #China #UrbanHealthcare #EnvironmentalImpact #AtopicDermatitis #MarketGrowth #CAGR #MarketPotential #PatientAwareness #DemographicTrends

9

🌟 𝐑𝐚𝐩𝐢𝐝 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐎𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 (𝐂𝐌𝐎) 𝐌𝐚𝐫𝐤𝐞𝐭! 🌟 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gABfjbrr The healthcare CMO market is experiencing significant growth, driven by the increasing demand for outsourced manufacturing services in the pharmaceutical, biotechnology, and medical device industries. Contract Manufacturing Organizations (CMOs) provide essential services that enable healthcare companies to focus on their core competencies, such as research and development, while ensuring high-quality production and regulatory compliance. 🔍 Key Market Drivers: Rising Demand for Pharmaceutical Products: The growing global demand for pharmaceuticals, including generics, biosimilars, and innovative drugs, is driving the need for efficient and scalable manufacturing solutions provided by CMOs. Cost Efficiency and Flexibility: Outsourcing manufacturing to CMOs allows healthcare companies to reduce operational costs, manage risks, and increase flexibility in production capacity, particularly during peak demand periods. Advancements in Biopharmaceuticals: The increasing complexity of biopharmaceutical products, such as monoclonal antibodies and cell and gene therapies, necessitates specialized manufacturing capabilities that many CMOs possess. 📊 Market Trends: Expansion of Biologics Manufacturing: With the rise of biologics and biosimilars, CMOs are investing in advanced biomanufacturing technologies to cater to this growing segment of the market. Focus on Quality and Compliance: Regulatory agencies are imposing stringent quality standards, driving CMOs to adopt advanced quality management systems and ensure compliance with Good Manufacturing Practices (GMP). Integration of Innovative Technologies: The adoption of cutting-edge technologies, such as single-use systems, continuous manufacturing, and automation, is enhancing the efficiency and scalability of CMO operations. #Company Accellent LLC Boehringer Ingelheim Catalent Pharma Solutions DSM FAREVA Greatbatch Medical Lonza Patheon Tecomet, Inc #Type Pharmaceutical Contract Manufacturing Services (Active Pharmaceutical Ingredients (API) Manufacturing, Final Dosage Form (FDF) Manufacturing, and Packaging) Medical Device Contract Manufacturing Services (Outsourcing Design, Device Manufacturing (Material Process Services, Electronic Manufacturing Services, and Finished Products), and Final Goods Assembly) Final Goods Assembly #Application Pharmaceutical Biotechnology Industry #HealthcareCMO #PharmaceuticalManufacturing #Biotechnology #MedicalDevices #HealthcareInnovation #ContractManufacturing #Biopharmaceuticals #MarketTrends #QualityCompliance #RegulatoryStandards #AdvancedManufacturing #IndustryCollaboration #PharmaTech #SustainableManufacturing #GMPCompliance #HealthcareAdvancements

3

Check out this newly published biopharma whitepaper from Citeline: "Precision Oncology Drug Development in China: Opportunities, Challenges, and Fast Paths Forward". Download the whitepaper here: https://lnkd.in/g5AfbRV5 Unlocking the potential of China’s biopharmaceutical market is essential in developing new cancer therapies using comprehensive genomic profiling tests. Guardant Health AMEA is breaking boundaries by enabling local and multinational biopharmaceutical companies in China to grow globally by accelerating oncology clinical research and trial enrolment. This whitepaper delves into the opportunities and challenges faced by China’s biopharmas and global biopharmas as well as fast paths forward in the field of precision oncology drug development in China. Contact our biopharma team at [email protected] to see how we can help you accelerate oncology clinical trials and bring the next generation of cancer therapies to patients sooner . Visit us at https://lnkd.in/gTvtVAJX to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #whitepaper #citeline #biopharma #CDx #companiondiagnostics #drugdevelopment #clinicaltrials #precisiononcology #oncologytrials #china #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

65

댓글 1

BrainLinx (BLX) was proud to have Heng Liu from I-Mab Biopharma as he shares his insights on "Value Creation Across Global Procurement and Supply Chain." For More Info DM at BLX Write Us→ [email protected] Visit Website→ www.brainlinx.com #brainlinx #innovation #Technology #packaging #sustainability #secondarypackaging #packagingsolutions #innovation #productdesign #Packagingtechnology #primarypackaging #2024events #management #pharmapackaging #conferences2024 #startup #event #supplychain #logistics

9

Our latest blog dives into the growing trend of collaboration among South Korean pharmaceutical firms. These strategic partnerships are transforming the industry, shifting from traditional co-marketing to innovative joint ventures in new drug development. Discover how these alliances are: 🔬 Advancing novel drug projects 🤝 Sharing resources and expertise 🌏 Making a significant impact in the Asian market Special mention to our team at Woodley BioReg for our successful collaborations with Korean partners, setting a stellar example of strategic cooperation in the pharmaceutical industry. Stay ahead in the pharma world - read the full blog now!

6

✨ Every Tuesday, stay at the forefront of #Oncology advancements! Today’s Pharma Daily Digest delivers essential insights and trends shaping the future of #cancer treatments. AQEMIA Secures $38M Funding Led by Cathay Innovation to Advance Oncology Research; $140M Collaboration with Sanofi Highlights Cutting-Edge Drug Discovery Platform AstraZeneca's Tagrisso has received approval in South Korea for the treatment of unresectable Stage-3 #lungcancer Regeneron Highlights Odronextamab’s Potential in #Lymphoma at #ASH 2024, Plans Resubmission for Regulatory Approval in 2025 Bristol Myers Squibb Highlights Breakthroughs in CAR T Therapies: Arlocabtagene Autoleucel Shows Promising Survival Data, Breyanzi® Reaffirms Long-Term Efficacy, and CD19 NEX-T® Expands Potential to #Autoimmune Diseases #Larotrectinib Achieves 94% Response Rate in #Pediatric #Cancer Trials, Solidifying Role as First-Line Therapy for NTRK Fusion-Positive Tumors Merck announced that its Phase 3 KEYLYNK-001 trial met the primary endpoint of progression-free survival (PFS) in patients with advanced #epithelial #ovarian cancer. Genmab and AbbVie announced that Epcoritamab, their subcutaneous bispecific antibody, delivered impressive results in CAR T-naïve B-cell #lymphoma patients, achieving a 61% overall response rate and a 45% complete response rate. CRISPR Therapeutics Forms Strategic Partnerships with Bayer and Vertex Pharmaceuticals to Advance #GeneEditing Innovations AstraZeneca celebrates 13 regulatory approvals, highlighting the success of #Calquence in #leukemia treatment at ASH 2024 Novartis presents promising Phase 3 trial results for Scemblix, positioning it as a strong contender for leukemia therapy Backed by Promising Phase 3 Results, Johnson & Johnson Submits Groundbreaking Regulatory Applications for DARZALEX® FASPRO® and Subcutaneous Formulation.   ----- 💡 Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #merck #AstraZeneca #Genmab #AbbVie #bms #Regeneron #JohnsonandJohnson

15

Watch the panel discussion on ‘Advances in Drug Discovery & Development 2024’ by Technology Networks in conversation with Clarivate experts - Matthew Arnold and Mike Ward - along with Hong I. Wan, CEO and Founder of Tallac Therapeutics, in the Clarivate Companies to Watch report. Gain insights on: ➡️ The history of ADC development, highlighting the challenges pharma companies face across the development and commercialization lifecycle and what they should consider when acquiring and using ADCs. ➡️ Current clinical activity and dealmaking in the ADC space, reflecting the growing maturity of ADC technologies. ➡️ The regulatory environment around ADCs and how it differs across key markets. ➡️ The challenges pharma companies face in developing linker technology. ➡️ What the next generation of ADCs will look like and their potential to address unmet therapeutic needs. View here: https://lnkd.in/eKMKKHWM #DrugDiscovery #Pharmaceuticals #ADCs #Regulatory #HealthcareLeadership

25

댓글 1

China's HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial 💉🧬 HanX Biopharmaceuticals, based in Hangzhou, China, is planning a Hong Kong IPO to fund the phase 2 trial of its lead drug, HX009. The drug, a PD-1/CD47-targeted bispecific, is currently in phase 1 trials for advanced melanoma and relapsed or refractory Epstein-Barr virus-positive non-Hodgkin lymphoma. The company has not disclosed the IPO target amount but prioritizes using the funds for its core product's development. It’s exciting to see HanX Biopharmaceuticals advancing HX009; its potential for treating solid tumors is really promising. Link in the comments for the full story. 🌐

3

댓글 1

𝐁𝐢𝐨𝐜𝐲𝐭𝐨𝐠𝐞𝐧 𝐚𝐧𝐝 𝐈𝐃𝐄𝐀𝐘𝐀 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐟𝐨𝐫 𝐅𝐢𝐫𝐬𝐭-𝐢𝐧-𝐂𝐥𝐚𝐬𝐬 𝐁𝟕𝐇𝟑/𝐏𝐓𝐊𝟕 𝐁𝐬𝐀𝐃𝐂 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 Biocytogen Pharmaceuticals (HKEX: 02315) Biocytogen, a global biotech company focused on novel antibody/ADC therapeutics, has entered an option and license agreement with IDEAYA Biosciences, Inc. (Nasdaq: IDYA) IDEAYA Biosciences for a potential first-in-class B7H3/PTK7 BsADC program. Dr. Yuelei Shen Yuelei Shen, President and CEO of Biocytogen, stated, “This partnership leverages our RenLite® platform and proprietary linker-payload technology to enhance ADC precision and potency. IDEAYA's expertise in drug development makes us confident in advancing this therapy to benefit patients.” Yujiro S. Hata Yujiro S. H., CEO of IDEAYA, added, “This BsADC program, developed as a monotherapy for multiple solid tumors, aligns with our strategy to combine ADCs with DDR-based therapies for greater patient benefit.” The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for the B7H3/PTK7 BsADC program. Biocytogen will receive an upfront fee and, upon option exercise by IDEAYA, additional milestone payments and royalties. Total potential payments could reach $406.5 million, including $100 million in development and regulatory milestones. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024. #Biotechnology #Pharmaceuticals #CancerResearch #ADCTherapeutics #Oncology #PrecisionMedicine #DrugDevelopment #Biocytogen #IDEAYA #Innovation #Healthcare #Partnership #LifeSciences

1